Evidence map›Paper›PMID 35781842›Full record

ArticleMikrochimica acta2022

A smartphone-based platform for ratiometric visualization of SARS-CoV-2 via an oligonucleotide probe.

Tingting Zhao, Weizhen Yan, Fengqi Dong, Xinlong Hu, Yanli Xu, Zhenyu Wang, Yating Shen, Wanrong Wang, Ye Zhao, Wenmei Wei

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tingting Zhao *School of Basic Medical Sciences, Biopharmaceutical Research Institute, Research and Engineering Center of Biomedical Materials, Anhui Medical University, Hefei, 230032, Anhui, China. ttzhao@ahmu.edu.cn.ORCID http://orcid.org/0000-0001-9376-6715
Weizhen Yan *The First School of Clinical Medicine, Anhui Medical University, Hefei, 230032, Anhui, China.
Fengqi DongSchool of Basic Medical Sciences, Biopharmaceutical Research Institute, Research and Engineering Center of Biomedical Materials, Anhui Medical University, Hefei, 230032, Anhui, China.
Xinlong HuSchool of Basic Medical Sciences, Biopharmaceutical Research Institute, Research and Engineering Center of Biomedical Materials, Anhui Medical University, Hefei, 230032, Anhui, China.
Yanli XuSchool of Basic Medical Sciences, Biopharmaceutical Research Institute, Research and Engineering Center of Biomedical Materials, Anhui Medical University, Hefei, 230032, Anhui, China.
Zhenyu WangThe First School of Clinical Medicine, Anhui Medical University, Hefei, 230032, Anhui, China.
Yating ShenThe First School of Clinical Medicine, Anhui Medical University, Hefei, 230032, Anhui, China.
Wanrong WangThe First School of Clinical Medicine, Anhui Medical University, Hefei, 230032, Anhui, China.
Ye ZhaoSchool of Basic Medical Sciences, Biopharmaceutical Research Institute, Research and Engineering Center of Biomedical Materials, Anhui Medical University, Hefei, 230032, Anhui, China. zhaoye@ahmu.edu.cn.
Wenmei WeiSchool of Basic Medical Sciences, Biopharmaceutical Research Institute, Research and Engineering Center of Biomedical Materials, Anhui Medical University, Hefei, 230032, Anhui, China. cherrywwm@ustc.edu.

Funding

Anhui Province Overseas Students Innovation Project Selection Funding Program-Key Projects 2021LCX003Excellent Young Talents Fund Program of Higher Education Institutions of Anhui Province gxyqZD2021102National Natural Science Foundation of China 21703255Natural Science Foundation of Anhui Province 1708085MB35Research Fund for Scientific Research Level Improvement Plan of Anhui Medical University 2020xkjT001Research Fund for the Doctoral Program of Anhui Medical University XJ201808Research Fund of Anhui Institute of Translational Medicine 2021zhyx-C17
6 · The paper itself

Abstract

COVID-19 necessitates the development of reliable and convenient diagnostic tools. In this work, a facile 3D-printed smartphone platform was constructed that achieved reliable visual detection of SARS-CoV-2 by eliminating the effect of ambient light and fixing the camera position relative to the sample. The oligonucleotide probe is modified with orange-red-emitting TAMRA working as an internal standard and green-emitting FAM serving as a sensitive sensing agent. Under 365-nm UV excitation, the emission wavelengths of TAMRA and FAM are 580 nm and 518 nm, respectively. When the probes interact with the targets, the green fluorescence gradually restores while the orange-red fluorescence remains stable. Thus, a striking color transition from orange-red to green could be observed by the naked eye. The detection limit of SARS-CoV-2 nucleic acid is 0.23 nM, and the entire process of color change could be completed in 25 min. Furthermore, the RGB value analysis of the sample solution was conducted using a smartphone for reliable and reproducible discrimination of SARS-CoV-2. The proposed smartphone platform might establish a general method for visual detection of SARS-CoV-2 nucleic acid as well as other virus-related diseases.

Indexed as

COVID-19SmartphoneFluorescenceHumansOligonucleotide ProbesSARS-CoV-2Oligonucleotide ProbesFluorescence resonance energy transferRatiometric probeSARS-CoV-2Smartphone-based detectionVisual detection

Identifiers

PMID35781842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.